Amyloid accumulation and degeneration of the cholinergic white matter pathways are key factors in early Alzheimer's disease pathogenesis and progression. However, the relationship between them remains unclear.
Objective
To investigate the association between amyloid accumulation, the integrity of cholinergic white matter pathways, and cognitive performance.
Methods
This cross-sectional study recruited 109 individuals, including 37 controls with normal cognition and 72 patients with early Alzheimer's disease. All participants underwent neuropsychological testing: the Mini-Mental Status Examination (MMSE), Clinical Dementia Rating scale with sum of box (CDR-SB), and verbal fluency tests. Cholinergic white matter integrity and amyloid burden were assessed through diffusion tensor imaging study (DTI) and amyloid positron emission tomography (PET). Stepwise linear regression analyses were performed. Partial correlations between amyloid burden and cholinergic integrity were also evaluated according to apolipoprotein E4 (APOE4) carrier status.
Results
Across all participants, amyloid burden and cholinergic integrity were independently associated with all cognitive performances. In subgroup analysis, amyloid burden was associated with MMSE only in the early Alzheimer's disease group (p = 0.012). Cholinergic integrity was significantly associated with all cognitive performances in the early Alzheimer's disease group (p < 0.05) but not in the control group. Amyloid burden remained significantly correlated with cholinergic integrity only in APOE4 noncarriers (p < 0.05) but not in APOE4 carriers.
Conclusions
Cholinergic white matter integrity, the severity of which is associated with amyloid burden, may be a specific imaging marker in early-stage Alzheimer's disease. In this study, this phenomenon was more pronounced in APOE4 noncarriers.
ZhangHJiangXLiH, et al.Role of Aβ in Alzheimer ‘s-related synaptic dysfunction. Front Cell Dev Biol2022; 10: 964075.
2.
MengXSongQLiuJ, et al.Neurotoxic β-amyloid oligomers cause mitochondrial dysfunction- trigger for PANoptosis in neurons. Front Aging Neurosci2024; 16: 1400544.
3.
NasrabadySERizviBBrickmanAM, et al.White matter changes in Alzheimer's disease: a focus on myelin and oligodendrocytes. Acta Neuropathol Commun2018; 6: 22.
4.
HironoNKitagakiHMoriE, et al.Impact of white matter changes on clinical manifestation of Alzheimer's disease: a quantitative study. Stroke2000; 31: 2182–2188.
5.
BatesKAFonteJHarveyAR, et al.Chronic gliosis triggers Alzheimer's disease-like processing of amyloid precursor protein. Neuroscience2002; 113: 785–796.
6.
MerluzziAPCarlssonCMJohnsonSC, et al.Neurodegeneration, synaptic dysfunction, and gliosis are phenotypic of Alzheimer dementia. Neurology2018; 91: e436–e443.
7.
GangulyABabuSSKapusettiG, et al.Advances and future trends in the detection of beta-amyloid: a comprehensive review. Med Eng Phys2025; 135: 104269.
8.
VonkJMJTwaitELGeerlingsMI, et al.Cross-sectional associations of amyloid burden with semantic cognition in older adults without dementia: a systematic review and meta-analysis. Mech Ageing Dev2020; 192: 111386.
9.
VillemagneVLOngKMulliganRS, et al.Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med2011; 52: 1210–1207.
10.
PikeKESavageGRoweCC, et al.Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain2007; 130: 2837–2844.
11.
JiaJNingYWangS, et al.Biomarker changes during 20 years preceding Alzheimer's disease. N Engl J Med2024; 390: 712–722.
12.
SchwarzCGGunterJLJackCR Jr, et al.A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity. Neuroimage Clin2016; 11: 802–812.
13.
DickersonBCStoubTRShahRC, et al.Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology2011; 76: 1395–1402.
14.
JackCR JrAndrewsJSCarrilloMC, et al.Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's association workgroup. Alzheimers Dement2024; 20: 5143–5169.
15.
JackCR JrLoweVJPetersenRC, et al.11C Pib and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain2008; 131: 665–680.
16.
HuijbersWMorminoECSchultzAP, et al.Amyloid-β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. Brain2015; 138: 1023–1035.
17.
BourgeatPChételatGVillemagneVL, et al.Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology2010; 74: 121–127.
18.
Garnier-CrussardABougachaSChételatG, et al.White matter hyperintensity topography in Alzheimer's disease and links to cognition. Alzheimers Dement2022; 18: 422–433.
19.
ShirzadiZSchultzSAChhatwalJP, et al.Dominantly inherited Alzheimer network and the Alzheimer’s disease neuroimaging initiative. Etiology of white matter hyperintensities in autosomal dominant and sporadic Alzheimer disease. JAMA Neurol2023; 80: 1353–1363.
20.
SchoemakerDZanon ZotinMCQuirozYT, et al.White matter hyperintensities are a prominent feature of autosomal dominant Alzheimer's disease that emerge prior to dementia. Alzheimers Res Ther2022; 14: 89.
21.
MortamaisMArteroSRitchieK. White matter hyperintensities as early and independent predictors of Alzheimer's disease risk. J Alzheimers Dis2014; 42: S393–S400.
22.
Van de HaarHJJansenJFAvan OschMJP, et al.Neurovascular unit impairment in early Alzheimer's disease measured with magnetic resonance imaging. Neurobiol Aging2016; 45: 190–196.
23.
MartinezJLZammitMDBhattacharyyaA, et al.Basal forebrain cholinergic neurons: linking down syndrome and Alzheimer's disease. Front Aging Neurosci2021; 13: 703876.
24.
SeldenNRGitelmanDRMesulamMM, et al.Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain1998; 121: 2249–2257.
25.
LeeLHLiuYCChouCJ, et al.White matter hyperintensities in cholinergic pathways may predict poorer responsiveness to acetylcholinesterase inhibitor treatment for Alzheimer's disease. PLoS One2023; 18: e0283790.
26.
CauncaMRWrightCBRundekT, et al.Cholinergic white matter lesions, AD-signature cortical thickness, and change in cognition: the northern Manhattan study. J Gerontol A Biol Sci Med Sci2020; 75: 1508–1515.
27.
NemyMDyrbaMBrosseronF, et al.Cholinergic white matter pathways along the Alzheimer's disease continuum. Brain2023; 146: 2075–2088.
28.
AlexanderALLeeJELazarM, et al.Diffusion tensor imaging of the brain. Neurotherapeutics2007; 4: 316–329.
29.
AssafYPasternakO. Diffusion tensor imaging (DTI)-based white matter mapping in brain research: a review. J Mol Neurosci2007; 34: 51–61.
30.
KantarciKMurrayMESchwarzCG, et al.White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. Neurobiol Aging2017; 56: 172–179.
31.
NirTMJahanshadNVillalon-ReinaJE, et al.Effectiveness of regional DTI measures in distinguishing Alzheimer's disease, MCI, and normal aging. Neuroimage Clin2013; 3: 180–195.
32.
ShirzadiZSchultzSAYauWW, et al.Etiology of white matter hyperintensities in autosomal dominant and sporadic Alzheimer disease. JAMA Neurol2023; 80: 1353–1363.
33.
Graff-RadfordJArenaza-UrquijoEMKnopmanDS, et al.White matter hyperintensities: relationship to amyloid and tau burden. Brain2019; 142: 2483–2491.
34.
CollijLEIngalaSTopH, et al.White matter microstructure disruption in early stage amyloid pathology. Alzheimers Dement (Amst)2021; 13: e12124.
35.
CedresNFerreiraDNemyM, et al.Association of cerebrovascular and Alzheimer disease biomarkers with cholinergic white matter degeneration in cognitively unimpaired individuals. Neurology2022; 99: e1619–e1629.
36.
WuDYuNGaoY, et al.Targeting a vulnerable septum-hippocampus cholinergic circuit in a critical time window ameliorates tau-impaired memory consolidation. Mol Neurodegener2023; 18: 23.
37.
YehFCPanesarSFernandesD, et al.Population-averaged atlas of the macroscale human structural connectome and its network topology. Neuroimage2018; 178: 57–68.
38.
YehFCLiuLHitchensTK, et al.Mapping immune cell infiltration using restricted diffusion MRI. Magn Reson Med2017; 77: 603–612.
39.
YehFCWedeenVJTsengWY. Generalized q-sampling imaging. IEEE Trans Med Imaging2010; 29: 1626–1635.
40.
YehFCVerstynenTDWangY, et al.Deterministic diffusion fiber tracking improved by quantitative anisotropy. PloS One2013; 8: e80713.
41.
YehFCPanesarSBarriosJ, et al.Automatic removal of false connections in diffusion MRI tractography using topology-informed pruning (TIP). Neurotherapeutics2019; 16: 52–58.
42.
NowrangiMALyketsosCGLeoutsakosJM, et al.Longitudinal, region-specific course of diffusion tensor imaging measures in mild cognitive impairment and Alzheimer's disease. Alzheimers Dement2013; 9: 519–528.
43.
FazekasFChawlukJBAlaviA, et al.MR Signal abnormalities at 1.5T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol1987; 149: 351–356.
44.
GeulaCNagykeryNNicholasA, et al.Cholinergic neuronal and axonal abnormalities are present early in aging and in Alzheimer disease. J Neuropathol Exp Neurol2008; 67: 309–318.
45.
BartusRTDean 3rdRLBeerB, et al.The cholinergic hypothesis of geriatric memory dysfunction. Science1982; 217: 408–414.
46.
KoizumiKHattoriYAhnSJ, et al.Apoε4 disrupts neurovascular regulation and undermines white matter integrity and cognitive function. Nat Commun2018; 9: 3816.
47.
Al-AminMMKimBKarahanH, et al.Apolipoprotein ε4 exacerbates white matter impairment in a mouse model of Aβ amyloidosis by decreasing actively myelinating oligodendrocytes. Alzheimers Dement2025; 21: e70791.
48.
WangYLChenWCaiWJ, et al.Associations of white matter hyperintensities with cognitive decline: a longitudinal study. J Alzheimers Dis2020; 73: 759–768.
49.
HuHYOuYNShenXN, et al.White matter hyperintensities and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 36 prospective studies. Neurosci Biobehav Rev2021; 120: 16–27.
50.
BrickmanAMProvenzanoFAMuraskinJ, et al.Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. Arch Neurol2012; 69: 1621–1627.
51.
Garnier-CrussardABougachaSWirthM, et al.White matter hyperintensity topography in Alzheimer's disease and links to cognition. Alzheimers Dement2022; 18: 422–433.
52.
YoshitaMFletcherEHarveyD, et al.Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD. Neurology2006; 67: 2192–2198.
53.
Garnier-CrussardABougachaSWirthM, et al.White matter hyperintensities across the adult lifespan: relation to age, Aβ load, and cognition. Alzheimers Res Ther2020; 12: 127.
54.
JoSCheongENKimN, et al.Role of white matter abnormalities in the relationship between microbleed burden and cognitive impairment in cerebral amyloid angiopathy. J Alzheimers Dis2022; 86: 667–678.
55.
YoonBShimYSCheongHK, et al.Interaction of white matter hyperintensities (WMHs) and apolipoprotein E (APOE) genotypes on cognition in patients with amnestic mild cognitive impairment (aMCI). Arch Gerontol Geriatr2013; 57: 292–297.
56.
MirzaSSSaeedUKnightJ, et al.APOE Ε4, white matter hyperintensities, and cognition in Alzheimer and Lewy body dementia. Neurology2019; 93: e1807–e1819.
57.
YuMCChuangYFLiuYC, et al.White matter hyperintensities in cholinergic pathways are associated with dementia severity in e4 carriers but not in non-carriers. Front Neurol2023; 14: 1100322.
58.
ToledoJBArnoldSERaibleK, et al.Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the national Alzheimer's coordinating centre. Brain2013; 136: 2697–2706.
59.
Neuropathology Group. Medical research council cognitive function and aging study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology group of the medical research council cognitive function and ageing study (MRC CFAS). Lancet2001; 357: 169–175.
60.
WeaverNADoevenTBarkhofF, et al.Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions. Neurobiol Aging2019; 84: 225–234.
61.
LiTRLiBLXuXR, et al.Association of white matter hyperintensities with cognitive decline and neurodegeneration. Front Aging Neurosci2024; 16: 1412735.
62.
McAleeseKEFirbankMDeyM, et al.Cortical tau load is associated with white matter hyperintensities. Acta Neuropathol Commun2015; 3: 60.
63.
McAleeseKEWalkerLCollobySJ, et al.Cortical tau pathology: a major player in fibre-specific white matter reductions in Alzheimer's disease?Brain2018; 141: e44.
64.
NohYSeoSWJeonS, et al.White matter hyperintensities are associated with amyloid burden in APOE4 non-carriers. J Alzheimers Dis2014; 40: 877–886.
65.
KoutsodendrisNBlumenfeldJAgrawalA, et al.APOE4-promoted Gliosis and degeneration in tauopathy are ameliorated by pharmacological inhibition of HMGB1 release. Cell Rep2023; 42: 113252.
66.
RaulinACDossSVHeckmanMG, et al.Impact of APOE on amyloid and tau accumulation in argyrophilic grain disease and Alzheimer's disease. Acta Neuropathol Commun2024; 12: 25.
67.
KoutsodendrisNBlumenfeldJAgrawalA, et al.Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits. Nat Aging2023; 3: 275–296.
68.
MontagneANikolakopoulouAMHuuskonenMT, et al.APOE4 Accelerates advanced-stage vascular and neurodegenerative disorder in old Alzheimer's mice via cyclophilin A independently of amyloid-β. Nat Aging2021; 1: 506–520.
69.
IngalaSMazzaiLSudreCH, et al.; ALFA Study. The relation between APOE genotype and cerebral microbleeds in cognitively unimpaired middle- and old-aged individuals. Neurobiol Aging2020; 95: 104–114.
70.
PiresMRegoAC. Apoe4 and Alzheimer's disease pathogenesis-mitochondrial deregulation and targeted therapeutic strategies. Int J Mol Sci2023; 24: 778.
71.
LumsdenALMulugetaAZhouA, et al.Apolipoprotein E (APOE) genotype-associated disease risks: a phenome-wide, registry-based, case-control study utilising the UK biobank. EBioMedicine2020; 59: 102954.
72.
LiMZhaoJVKwokMK, et al.Age and sex specific effects of APOE genotypes on ischemic heart disease and its risk factors in the UK Biobank. Sci Rep2021; 11: 9229.
73.
ChételatGVillemagneVLPikeKE, et al.Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. Brain2011; 134: 798–807.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
